Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-pretreated EGFR Exon 20 Insertion-Mutated NSCLC - supplementary material

Supplementary MethodsSupplementary ResultsSupplemental Table 1. Naïve and population-adjusted estimates of ORR and CBR for amivantamab: sensitivity analyses Supplemental Figure 1. Histogram of the weights associated with matching in the a) base case analysis; b) adjusting for additional factors and c) using the CHRYSALIS primary efficacy population (n = 81) Supplemental Figure 2. Sensitivity analysis results of PFS of amivantamab versus mobocertinib a) adjusting for additional factors and b) using the CHRYSALIS primary efficacy population (n = 81) Supplemental Figure 3. Sensitivity analysis results of OS of amivantamab versus mobocertinib a) adjusting for additional factors and b) using the CHRYSALIS primary efficacy population (n = 81) Supplemental Figure 3. Sensitivity Analysis: Population-adjusted safety outcomes for amivantamab in the safety population (matched for an additional four factors) and mobocertinib in the PPP population Supplemental Figure 4. Sensitivity Analysis: Population-adjusted safety outcomes for amivantamab in the n = 81 population and mobocertinib in the PPP population